drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (autologous CAR T cells)
drug_description
Autologous, gene-engineered T cells expressing a dual chimeric antigen receptor targeting BCMA (TNFRSF17) and GPRC5D on myeloma cells to activate T-cell cytotoxicity and eliminate malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-engineered to express dual chimeric antigen receptors recognizing BCMA (TNFRSF17) and GPRC5D on myeloma cells. Binding triggers CAR signaling (CD3z with costimulatory domains), activating T-cell proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity to eliminate malignant plasma cells while reducing antigen escape.
drug_name
BCMA-GPRC5D CAR-T cells
nct_id_drug_ref
NCT06644443